Contraception Clinical Trial
— NNM2Official title:
Navigating New Motherhood 2: Patient Navigation to Improve Outcomes Among Low-income Women in the Postpartum Period
Verified date | March 2024 |
Source | Northwestern University |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The primary aim of this study is to determine whether implementation of a postpartum patient navigation program improves health outcomes among low-income women. Patient navigation is a barrier focused, long-term patient-centered intervention that offers support for a defined set of health services. The intervention under investigation is a comprehensive postpartum patient navigator program. Women who are randomized to receive patient navigation will be compared to women who are randomized to receive usual care. Navigators will support women through one year postpartum. The NNM2 program will be grounded in understanding and addressing social determinants of health in order to promote self-efficacy, enhance access, and sustain long-term engagement. Participants will undergo surveys, interviews, and medical record review at 4-12 weeks and 11-13 months postpartum. The investigators will additionally conduct focus groups and surveys with clinical providers.
Status | Active, not recruiting |
Enrollment | 405 |
Est. completion date | December 2024 |
Est. primary completion date | July 2024 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Female |
Age group | 16 Years to 50 Years |
Eligibility | Inclusion Criteria: - Pregnant (any plurality) delivering at or after 20 weeks of gestation OR postpartum (during hospitalization), regardless of perinatal outcome - 16 years or older - Low-income socioeconomic status (publicly funded prenatal care) - Ability to speak and read English or Spanish - Established patient at the Northwestern Medicine Prentice Ambulatory Care clinical site (at least one antenatal clinical visit). Exclusion Criteria: - Intent to transfer care to an outside institution - HIV (as these patients already receive intensive social support and navigation-like services at this institution) - Prior pregnancy in which individual declined participation - Prior enrollment in NNM2 - Enrollment in a concurrent research study that poses a potential conflict to the aims of either NNM2 or the other study |
Country | Name | City | State |
---|---|---|---|
United States | Northwestern Memorial Hospital | Chicago | Illinois |
Lead Sponsor | Collaborator |
---|---|
Northwestern University | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Clinician perspectives on patient navigation | Qualitative feedback on how NNM2 can meet the needs of the clinicians and optimize postpartum care and the transition to primary care, as assessed by feedback from obstetrician and primary care provider focus groups | Through completion of study, an average of 3 years | |
Other | Clinician experiences with NNM2 | Number of clinicians who believed NNM2 met their needs and improved patient care, as determined by survey feedback obtained at the time of participants' postpartum visits | Through completion of study, an average of 5 years | |
Other | Navigation intensity and activities | Mixed methods data on navigation intensity (number of interactions over the postpartum year), types of activities completed for/with participants, types of communication modes used, and numbers/types of other health care team members involved in navigation activities. Data will be integrated from navigator weekly logs of navigation activities and quarterly in-depth qualitative interviews with the navigators. | Through completion of study, an average of 5 years | |
Primary | Postpartum health at 4-12 weeks after delivery | Number of women who achieve a composite measure of health status that includes retention in care, receipt of recommended counseling (anticipatory guidance), receipt of desired contraception, postpartum depression screening and care, breastfeeding initiation and maintenance, and receipt of preventive care. Components of the primary outcome composite will also be examined as a score and individually as secondary outcomes (see below). (Outcome is modified to include receipt telemedicine when appropriate for health care for women who require postpartum care during the pandemic) | 4-12 weeks postpartum | |
Secondary | Retention in care (component of primary outcome) | Number of participants who return for comprehensive medical care at least once between 4 and 12 weeks postpartum. | 4-12 weeks postpartum | |
Secondary | Receipt of recommended counseling/anticipatory guidance (component of primary outcome) | Number of participants who have been counseled about indicated topics recommended for postpartum care/health | 4-12 weeks and 1 year postpartum | |
Secondary | Receipt of desired contraception (component of primary outcome) | Among participants who desire a contraceptive method, number of participants who received their chosen method | 4-12 weeks and 1 year postpartum | |
Secondary | Postpartum depression screening and care (component of primary outcome) | Number of participants who undergo appropriate screening for postpartum depression with either 1) screening that indicates no depressive symptoms, or 2) if depressive symptoms are identified, patient receives further care | 4-12 weeks and 1 year postpartum | |
Secondary | Breastfeeding initiation and maintenance (component of primary outcome) | Among participants who desire to breastfeed, number of participants who have initiated and maintained exclusive or partial breastfeeding | 4-12 weeks postpartum | |
Secondary | Receipt of preventive care (component of primary outcome) | Number of participants who received indicated vaccines (e.g. influenza, TDaP, HPV, MMR; based on individual need) and screening tests (e.g. cervical cytology, pelvic/breast exams) by 12 weeks postpartum | 4-12 weeks postpartum | |
Secondary | Postpartum diabetes screening | Among women with gestational diabetes mellitus (GDM), number of women with completion of a 2-hour oral glucose tolerance test by 12 weeks postpartum | 4-12 weeks and 1 year postpartum | |
Secondary | Postpartum atherosclerotic cardiovascular disease screening | Among women with ASCVD-associated adverse pregnancy outcomes, number of women who undergo indicated clinical assessments for blood pressure, lipids, weight, nutrition, activity | 4-12 weeks and 1 year postpartum | |
Secondary | Gestational weight retention | Difference between weight at delivery and 1) weight at early postpartum (4-12 weeks) and 2) weight at 1 year postpartum | 4-12 weeks and 1 year postpartum | |
Secondary | Breastfeeding duration | Total duration of exclusive or partial breastfeeding among women who desired breastfeeding | 4-12 weeks and 1 year postpartum | |
Secondary | Postpartum transition to primary care | Number of women with appointment made and kept for primary care by 1 year postpartum | 1 year postpartum | |
Secondary | Patient-reported outcomes - self-efficacy, activation, engagement, quality of life, and other PROs | Differences in self-efficacy, activation, quality of life, engagement, and other PROs between women who are randomized to navigation versus usual care, using the DHHS PROMIS and other validated measures of PROs.
PROs to be measured include global health status (PROMIS Global Health), health literacy (Newest Vital Sign), depressive symptoms (Patient Health Questionnaire-9), pregnancy experience and pregnancy-related stress (Pregnancy Experience Scale - Brief, at 4-12 weeks only), patient activation (Patient Activation Measure), health-related self-efficacy (PROMIS Self-Efficacy - general), informational support (PROMIS Informational Support), perceived stress (Perceived Stress Scale), breastfeeding self-efficacy (Breastfeeding Self-Efficacy Scale), postpartum preparedness (Postpartum Preparedness Checklist), and satisfaction with prenatal and postpartum care (original and adaptation of Prenatal Care Satisfaction Scale). |
4-12 weeks and 1 year postpartum | |
Secondary | Patient-reported outcomes - experiences with navigation (survey) | Navigated participants' experiences with navigation as assessed through PRO surveys (Patient Satisfaction with Interpersonal Relationship with Navigator Scale and Patient Satisfaction with Logistical Aspects of Navigation Scale). | 4-12 weeks and 1 year postpartum | |
Secondary | Experiences with navigation (qualitative) | Qualitative perspectives on experiences with the navigation program, based on interviews with women who received navigation | 3-6 months postpartum and 1 year postpartum | |
Secondary | Pregnancy/postpartum experiences during the pandemic | Qualitative perspective of participants' experiences during the COVID-19 pandemic, utilizing a semi-structured interview guide developed by the research team, as it relates to their receipt of health care, experiences as a pregnant person and new parent, and the role of patient navigation in this time period | At any point during the COVID-19 pandemic, up to 3 months after the end of the pandemic |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02577601 -
Impact of Combined Hormonal Contraceptives on UPA
|
Phase 4 | |
Completed |
NCT03153644 -
Improving Contraceptive Care for Women With Medical Conditions
|
||
Completed |
NCT04112095 -
Adherence With Continuous-dose Oral Contraceptive: Evaluation of Self-Selection and Use
|
Phase 3 | |
Recruiting |
NCT05521646 -
Implementing Best Practice Postpartum Contraceptive Services Through a Quality Improvement Initiative
|
N/A | |
Active, not recruiting |
NCT04291001 -
Ovarian Function With ENG Implant and UPA Use
|
Early Phase 1 | |
Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
Completed |
NCT03438682 -
Real World Effectiveness and Safety of Hysteroscopic (Essure®) Compared to Laparoscopic Sterilization
|
||
Active, not recruiting |
NCT01948882 -
Evaluation of Safety and Effectiveness of the Essure (Model ESS505) Device to Prevent Pregnancy in Women
|
N/A | |
Enrolling by invitation |
NCT04997499 -
Adolescent Subcutaneous (SQ) Injection Video Validation
|
N/A | |
Recruiting |
NCT03589040 -
Darunavir and Rilpivirine Interactions With Etonogestrel Contraceptive Implant
|
Phase 2 | |
Completed |
NCT04463680 -
Rifampin and the Contraceptive Implant
|
Phase 4 | |
Completed |
NCT03154125 -
Sayana® Press Extension Study
|
Phase 3 | |
Withdrawn |
NCT03725358 -
A Cluster-RCT to Increase the Uptake of LARCs Among Adolescent Females and Young Women in Cameroon.
|
N/A | |
Completed |
NCT02957630 -
"E4/DRSP Endocrine Function, Metabolic Control and Hemostasis Study"
|
Phase 1/Phase 2 | |
Completed |
NCT02456584 -
Pharmacodynamics and Pharmacokinetics Study of Existing DMPA Contraceptive Methods
|
Phase 1 | |
Completed |
NCT02718222 -
Impact and Performance of Institutionalizing Immediate Post-partum IUD Services
|
N/A | |
Recruiting |
NCT02121067 -
LNG-IUS at 2 Weeks Postpartum
|
Phase 4 | |
Terminated |
NCT02169869 -
Immediate Postplacental IUD Insertion
|
N/A | |
Recruiting |
NCT02292056 -
Medication Safety and Contraceptive Counseling for Reproductive Aged Women With Psychiatric Conditions
|
N/A | |
Withdrawn |
NCT01930994 -
Kenya Sino-implant (II) PK Study
|
N/A |